Superline Technology: Termination of Targeted Share Issuance

Source: Suhang Technology, "Announcement on Resolutions of the Second Extraordinary Shareholders' Meeting in 2026"

DentalGoodNews｜On September 14, 2026, Shenzhen NEEQ-listed company Shenzhen Superline Technology Co.,LTD (hereinafter referred to as "Superline Technology", 874313.NQ) released the "Announcement on Resolutions of the Second Extraordinary Shareholders' Meeting in 2026". The company's shareholders' meeting held on September 11 deliberated and approved the "Proposal on Terminating the Targeted Issuance of Shares", with all attending shareholders (representing 100% of the total voting shares of the company) voting unanimously in favor. The voting procedures were witnessed by a law firm and confirmed as lawful and valid.

According to the announcement, Superline Technology previously received the "Letter of Approval Regarding the Targeted Issuance of Shares of Shenzhen Superline Technology Co.,LTD" issued by the National Equities Exchange and Quotations (NEEQ) on September 26, 2025, with a validity period of 12 months.

After obtaining the approval letter, although the company actively advanced investor selection work, as of the time stated in the announcement, the final issuance targets had not yet been determined, nor had the subscription and payment verification procedures been initiated. Based on strategic planning and future development, and in light of the company's actual circumstances, the company decided to terminate this targeted issuance.

Superline Technology was founded in 2002 by three doctors of materials science. It is primarily engaged in the research, development, and sales of dental medical devices such as nickel-titanium endodontic treatment instruments, orthodontic archwires, and high-speed diamond burs.

According to Superline Technology's 2026 semi-annual report, the company achieved operating revenue of 42.3015 million yuan in the first half of 2026, a decrease of 5.22% compared to the same period last year. Among this, the endodontic series products achieved revenue of 36.6172 million yuan, with a Gross Margin of 47.65%, and the orthodontic series products achieved revenue of 4.7238 million yuan, with a Gross Margin of 39.83%.

During the reporting period, the company achieved a net profit attributable to shareholders of the listed company of 614,200 yuan, a year-on-year decrease of 71.47%, mainly due to new products being in the capacity ramp-up stage and having not yet reached designed capacity, with fixed costs being diluted resulting in relatively high unit costs.